FDA Clearance Tracker · K252512
Armada 14 NC PTA Catheter
Last checked: Nov 19, 2026Latest source record: Feb 13, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Feb 13, 2026
Substantially Equivalent
Time to decision
186 days
Received Aug 11, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K252512
- Device name
- Armada 14 NC PTA Catheter
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Santa Clara, CA
- Received
- Aug 11, 2025
- Decided
- Feb 13, 2026
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 870.1250
- Specialty
- CardiologyInterventional Cardiology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LIT. The earliest in FDA's data is K803057, decided Jan 13, 1981.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K252512
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
- EnSite X EP System510(k)
K261729 · Decided Sep 17, 2026 · 114 days after receipt
Device type: Computer, Diagnostic, Programmable (DQK) · Cardiology
- TactiFlex Duo Ablation Catheter, Sensor Enabled (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDMPMA supplement
P220013-S028 · Decided Sep 4, 2026 · 186 days after receipt · Panel Track
Device type: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation (OAE) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.